Alkermes plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALKS Nasdaq 2836 www.alkermes.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alkermes plc

4 CNS Drug Stocks Worth Watching This World Mental Health Day - Oct 9th, 2026 7:28 am
Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity? - Oct 9th, 2026 3:13 am
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS) - Oct 5th, 2026 7:48 am
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? - Sep 30th, 2026 10:47 am
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Sep 25th, 2026 9:59 pm
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - Sep 23rd, 2026 5:13 am
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says - Sep 22nd, 2026 9:39 am
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Sep 22nd, 2026 9:15 am
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide - Sep 22nd, 2026 8:17 am
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won - Sep 21st, 2026 2:15 pm
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - Sep 21st, 2026 6:41 am
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - Sep 21st, 2026 5:00 am
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Sep 16th, 2026 5:00 am
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Sep 10th, 2026 5:00 am
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - Aug 29th, 2026 1:00 pm
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report? - Aug 27th, 2026 9:30 am
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 - Aug 24th, 2026 4:30 pm
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Aug 21st, 2026 10:40 am
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Aug 21st, 2026 8:48 am